New Results from the Phase 2b TIME Trial, Including the Correlation of Vaccine-Induced Immunogenicity and Improved Overall Survival, Support Transgene’s Ongoing Clinical Strategy to Develop TG4010 in Lung Cancer (NSCLC) in Combination Regimens with Immune Checkpoint Inhibitors (ICIs)
Strasbourg, France, October 30, 2017, 5:45 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops viral-based immunotherapies, will be presenting a poster on additional immunology data generated from the randomized, placebo-controlled Phase 2b trial (TIME) that evaluated the combination regimen of TG4010 and chemotherapy in patients with advanced lung cancer at the Society for Immunotherapy of Cancer (SITC) Meeting 2017, in National Harbor, Maryland, November 8-12.
Poster title: Immune mechanisms of the response to TG4010, a viral-based vaccine, in patients with advanced non-small cell lung carcinoma
• Poster ID: P137
• Date, time, location: Saturday, November 11, 2017, 12:30 – 2:00 pm and 6:30 – 8:00 pm
The abstract will be published on November 7, 2017, on the SITC website.
.../...
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer